SYSA-1801

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSYSA-1801
Drug Alias NameSYSA-1801SYSA1801CPO-102EO-3021
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18Tubulin polymerisation inhibitors
TargetsClaudin-18 splice variant 2Tubulin
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursPancreatic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJushi Biopharmaceutical Co Ltd
Inactive CompaniesConjupro Biotherapeutics IncCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Pharmaceutical Group Ltd +[4] 
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms
Inactive IndicationsPancreatic NeoplasmsEsophageal NeoplasmsGastrointestinal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A